These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36305799)

  • 21. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
    Hisamatsu T; Kato S; Kunisaki R; Matsuura M; Nagahori M; Motoya S; Esaki M; Fukata N; Inoue S; Sugaya T; Sakuraba H; Hirai F; Watanabe K; Kanai T; Naganuma M; Nakase H; Suzuki Y; Watanabe M; Hibi T; Nojima M; Matsumoto T;
    J Gastroenterol; 2019 Oct; 54(10):860-870. PubMed ID: 31041545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
    Preda CM; Fulger LE; Negreanu L; Manuc M; Sandra I; Diculescu MM
    Rev Esp Enferm Dig; 2016 Oct; 108(10):642-647. PubMed ID: 27651132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
    Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
    Varma P; Paul E; Huang C; Headon B; Sparrow MP
    Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
    Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
    Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation.
    Bronsky J; Copova I; Kazeka D; Lerchova T; Mitrova K; Pospisilova K; Sulovcova M; Zarubova K; Hradsky O
    Clin Transl Gastroenterol; 2022 May; 13(5):e00490. PubMed ID: 35363628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The shining DIAMOND for evidence-based treatment strategies for Crohn's disease.
    Nakase H; Matsumoto T; Watanabe K; Hisamatsu T
    J Gastroenterol; 2020 Sep; 55(9):824-832. PubMed ID: 32661927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn's Disease.
    Jung YS; Han M; Park S; Cheon JH
    Gut Liver; 2021 Jan; 15(1):92-99. PubMed ID: 32839359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
    Tursi A; Mocci G; Lorenzetti R; Allegretta L; Brandimarte G; Cassieri C; Colucci R; De Medici A; Faggiani R; Ferronato A; Fiorella S; Forti G; Franceschi M; Gallina S; Giorgetti G; Grasso G; Larussa T; Luzza F; Penna A; Pica R; Piergallini S; Porciello S; Pranzo G; Rodino' S; Scorza S; Sebkova L; Zampaletta C; Elisei W; Picchio M
    Eur J Gastroenterol Hepatol; 2021 May; 33(5):670-679. PubMed ID: 33741797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.
    Kopylov U; Al-Taweel T; Yaghoobi M; Nauche B; Bitton A; Lakatos PL; Ben-Horin S; Afif W; Seidman EG
    J Crohns Colitis; 2014 Dec; 8(12):1632-41. PubMed ID: 25067824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
    Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS
    J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease.
    Hoekman DR; Stibbe JA; Baert FJ; Caenepeel P; Vergauwe P; De Vos M; Hommes DW; Benninga MA; Vermeire SA; D'Haens GR;
    J Crohns Colitis; 2018 Apr; 12(5):517-524. PubMed ID: 29401297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
    Gordon M; Taylor K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn's Disease Patients.
    Kim ES; Kwon Y; Choe YH; Kim MJ
    Gut Liver; 2022 Jan; 16(1):71-80. PubMed ID: 34092576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study.
    Bastida G; Marín-Jiménez I; Forés A; García-Planella E; Argüelles-Arias F; Tagarro I; Fernandez-Nistal A; Montoto C; Aparicio J; Aguas M; Santos-Fernández J; Boscá-Watts MM; Ferreiro-Iglesias R; Merino O; Aldeguer X; Cortés X; Sicilia B; Mesonero F; Barreiro-de Acosta M
    Dig Liver Dis; 2022 Jan; 54(1):76-83. PubMed ID: 34244110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease.
    Macaluso FS; Ventimiglia M; Fries W; Viola A; Sitibondo A; Cappello M; Scrivo B; Busacca A; Privitera AC; Camilleri S; Garufi S; Di Mitri R; Mocciaro F; Belluardo N; Giangreco E; Bertolami C; Renna S; Orlando R; Rizzuto G; Cottone M; Orlando A;
    J Gastroenterol Hepatol; 2021 Jan; 36(1):105-111. PubMed ID: 32428981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.